AEON Biopharma, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $AEON in the last 7 days.
No SEC Form 4 filings for $AEON in the last 30 days.
See all $AEON insider activity →Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.
Aeon Biopharma reported positive results from a stress test comparing its ABP-450 treatment to Botox, showing similar degradation under thermal and oxidative stress. The company plans a multi-lot comparability study. Shares of Aeon were up 1% to 23 cents, with a market cap of $11.8 million.
On Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp
Recent AEON coverage spans financial news, technology and earnings.
Positive analytical data may de‑risk the biosimilar program.
Positive comparability data may boost confidence in ABP‑450 and support future development milestones.
Insider buying at low price could support short-term rally.
The filing reveals a significant shareholder stake, potentially influencing voting outcomes and future corporate actions.
Insider buying may signal confidence, modest upward pressure on AEON stock.
AlphAI scores every news story that mentions AEON with an AI model for sentiment and relevance, and aggregates insider trades from AEON Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.
3 min readAeon Biopharma reported positive results from a stress test comparing its ABP-450 treatment to Botox, showing similar degradation under thermal and oxidative stress. The company plans a multi-lot comparability study. Shares of Aeon were up 1% to 23 cents, with a market cap of $11.8 million.
2 min readOn Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp
3 min readAEON Biopharma (AEON) filed a Schedule 13G reporting that Timothy P. Lynch owns 6,500,000 shares (13% of Class A stock). Lynch has sole voting and dispositive power over these shares. The filing also notes additional warrants for 7,000,000 shares are blocked due to a 4.99% ownership cap.
2 min readLYNCH TIMOTHY P purchased 1,150,000 shares of AEON Biopharma, Inc. (AEON) at $0.21 ($0.24M total) on 2026-08-19.
1 min readAEON Biopharma reported expanded data supporting molecular similarity of ABP-450 to BOTOX, achieving 98% sequence coverage with 100% amino acid identity. Preliminary analysis confirmed critical disulfide bond structure. FDA feedback expected to guide next development phase. ABP-450 aims for full-label U.S. market entry as a biosimilar to BOTOX.
2 min readAEON Biopharma reported Q2 results showing its net loss narrowed, helped by gains from warrants, according to the company. The firm also said its cash runway has been extended, citing improved liquidity. The update provides investors with a view of near-term funding and operating performance.
2 min readAEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advanceme
6 min readAeon, the Japanese retailer, is exiting its Thailand supermarket business after more than four decades, according to the report. It is selling the unit to Central Group, citing pressure on consumption from a slowing economy. Aeon says it will shift its regional growth focus toward Vietnam.
2 min readCentral Retail said its unit Central Food Retail will acquire all AEON (Thailand) ordinary shares, after signing an agreement filed Aug. 7. Completion is expected Sept. 30. MaxValu stores will be rebranded as Tops and integrated. AEON exits Thai supermarkets after 40+ years, while prioritizing Vietnam, where AEON Mall reported FY2024 revenue of about 17.3bn yen (+14%).
5 min read
